Business | Schumpeter

Lessons from Novo Nordisk on the stampede for obesity drugs

Dos and don’ts on how to handle a gold rush

Paul Ingram, who manages a ranch in rural Texas, is not the type you would normally associate with a weight-loss fad. But a year ago he finally got fed up with lugging his 320lb (145kg) frame around all day in the heat. His family has a history of heart disease. As a result of covid-19, he had become painfully aware of the risks of obesity. His efforts to lose weight through diet and exercise had gone nowhere. “I needed some help.”

This article appeared in the Business section of the print edition under the headline “De Novo”

From the March 4th 2023 edition

Discover stories from this section and more in the list of contents

Explore the edition

More from Business

Illustration of two wolf cubs sitting on the head of the wall street bull

Meet the ambitious wolf cubs of Wall Street

A duo of whippersnappers is taking on Goldman Sachs 

What next for US Steel?

The faded industrial icon has few good options without a Nippon deal


Foxconn's Model D electric vehicle .

Foxconn and other gadget-makers are expanding their empires

The world’s contract manufacturers are moving into new products and places


The signals of workplace submissiveness

Deference is all around you, unfortunately

America’s internet giants are being outplayed in the global south

From e-commerce to online banking, regional competitors are innovating rapidly

Will Mark Zuckerberg’s Trump gamble pay off?

He risks making enemies elsewhere